Neuromyelitis Optica Spectrum Disorder (NMOSD), formerly known as Devic's disease, is a rare autoimmune demyelinating disorder of the central nervous system characterized by severe inflammation of the optic nerves (optic neuritis) and spinal cord (myelitis). Once considered a variant of multiple sclerosis, NMOSD is now recognized as a distinct entity with unique pathophysiology, clinical course, and treatment approaches.
The key pathogenic feature of NMOSD is the presence of autoantibodies against aquaporin-4 (AQP4), the most abundant water channel in the central nervous system, located primarily on astrocytes. These antibodies drive a complement-mediated inflammatory process that leads to destructive lesions.
- Prevalence: 1-10 per 100,000 population
- Geographic variation: Higher prevalence in Asian, African, and Latin American populations
- Age of onset: Mean 30-40 years (range: <10 to >70)
- Gender distribution: Strong female predominance (F:M = 9:1)
- Incidence: Approximately 0.5-4 per 100,000 person-years
The female predominance is striking and suggests hormonal factors may influence disease expression.
¶ Aquaporin-4 and Astrocyte Biology
The AQP4 gene encodes aquaporin-4, a water channel protein highly expressed on astrocytic end-feet in the brain and spinal cord:
- Location: Perivascular and pial astrocyte processes
- Function: Water homeostasis, glutamate clearance, potassium buffering
- Expression: Highest in optic nerve, spinal cord, hypothalamus, circumventricular organs
- Structure: Orthogonal array of particles (OAPs) visible on electron microscopy
¶ Autoantibody Pathogenesis
Anti-AQP4 IgG antibodies drive NMOSD through:
- Antibody binding: Targets extracellular loop of AQP4 protein
- Complement activation: IgG1 isotype fixes complement
- Membrane attack complex formation: Leads to astrocyte destruction
- Inflammatory cascade: Recruitment of inflammatory cells
- Demyelination: Secondary to astrocyte injury
NMOSD must be distinguished from MOG-antibody disease (MOGAD):
- AQP4+ NMOSD: Astrocyte targeting, complement-mediated injury
- MOGAD: Oligodendrocyte targeting, complement-independent
- Optic neuritis: Unilateral or bilateral; often severe vision loss
- Acute myelitis: Transverse myelitis, often severe with long lesions
- Area postrema syndrome: Intractable hiccups, nausea, vomiting
- Brainstem syndrome: Cranial nerve involvement, diplopia
- Diencephalic syndrome: Narcolepsy, endocrine dysfunction
- Relapsing course: 80-90% of patients; more common in women
- Monophasic course: Single attack; more common in children
- Severe attacks: Often leave residual deficits
NMOSD diagnosis requires:
- Core clinical characteristics: Optic neuritis, myelitis, area postrema syndrome, etc.
- AQP4-IgG positivity: Using cell-based assay
- Exclusion of alternative diagnoses
- AQP4-IgG testing: Serum and CSF (serum more sensitive)
- MRI brain and spine: Characteristic lesions
- Optical coherence tomography: Optic nerve atrophy
- CSF analysis: May show pleocytosis
- Multiple sclerosis (MS)
- MOG-antibody disease (MOGAD)
- Acute disseminated encephalomyelitis (ADEM)
- Other autoimmune encephalitides
- High-dose intravenous corticosteroids: First-line
- Plasma exchange: For refractory attacks
- IVIG: Alternative or adjunctive therapy
First-line agents:
- Rituximab: Anti-CD20 monoclonal antibody
- Eculizumab/Ravulizumab: Complement C5 inhibitors
- Inebilizumab: Anti-CD19 monoclonal antibody
- Satralizumab: IL-6 receptor antagonist
Second-line agents:
- Mycophenolate mofetil
- Azathioprine
- Methotrexate
- Attack-related disability: Often severe residual deficits
- Visual outcomes: Significant vision loss common
- Mortality: Improved with modern immunotherapy
- Prognosis factors: Age, attack severity, treatment response
- Biomarker development: Predicting relapse and treatment response
- Pathogenesis studies: Understanding AQP4 autoimmunity
- Novel therapeutics: New complement inhibitors, B-cell targets
- Pediatric NMOSD: Distinct clinical features
Recent advances in NMOSD treatment include:
- Ravulizumab (Ultomiris): Long-acting complement C5 inhibitor showing sustained efficacy (PMID: 38550000)
- Inebilizumab (Uplizna): Anti-CD19 B-cell depletion therapy approved for AQP4+ NMOSD
- Satralizumab (Enspryng): IL-6 receptor blockade reducing relapse risk
- Eculizumab (Soliris): First FDA-approved therapy for AQP4+ NMOSD (Pittock 2019)
- AQP4-IgG titers: Predict relapse risk and treatment response
- Neurofilament light chain (NfL): Marker of axonal damage and disease activity
- Glial fibrillary acidic protein (GFAP): Astrocyte-specific biomarker